Fig 1.
This study included 1,111 patients with available baseline MPV measurement and successful TAVR procedure between February 2010 and May 2019. MPV was ≤10 fL (defined as low MPV) in 398 patients and >10 fL (high MPV) in 713 patients. Follow-up was completed for the primary outcome at one year for 1,078 patients (97.0%). Abbreviations: MPV = mean platelet volume; TAVR = transcatheter aortic valve replacement.
Table 1.
Demographic characteristics.
Table 2.
Biological findings prior to TAVR.
Fig 2.
Impact of baseline mean platelet volume on the incidence of major/life-threatening bleeding complications at one year follow-up after TAVR.
This figure shows the cumulative incidence of MLBCs during the first year after TAVR according to baseline MPV. Low MPV was defined as a baseline MPV ≤10 fL and high MPV as a baseline MPV >10 fL. Abbreviations: MLBCs = major and life-threatening bleeding complications; MPV = mean platelet volume; TAVR = transcatheter aortic valve replacement.
Table 3.
Outcomes during first year after TAVR.
Fig 3.
Impact of baseline mean platelet volume and postprocedural CT-ADP on the incidence of major/life-threatening bleeding complications at one year follow-up.
This figure shows the impact of baseline MVP and postprocedural CT-ADP value on the incidence of major/life-threatening bleedings. Patients were stratified according to baseline MPV (threshold 10 fL) and postprocedural CT-ADP value (threshold 180 s). Abbreviations: CT-ADP = closure time adenosine diphosphate; MPV = mean platelet volume; TAVR = transcatheter aortic valve replacement.
Table 4.
Univariate and multivariate analyses for occurrence of major/life-threatening bleeding during the first year after TAVR.
Table 5.
Univariate and multivariate logistic regression analyses for mean platelet volume ≤10 fL at baseline.